Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 3:20 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 205 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: levonorgestrel Clear all

Conditions: Sexually Transmitted Infection
Interventions: Not listed
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 2
States / cities: Boston, Massachusetts • Providence, Rhode Island

Conditions: Atopic Dermatitis
Interventions: PF-08049820, Midazolam, Dabigatran Etexilate, Portia (EE and LN) or equivalent oral tablet; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Genital Tract Mucosal Immunity, Genital Tract Microflora
Interventions: IUD placement, Levonorgestrel IUD, Copper T380A IUD; Drug
Lead sponsor: Sharon Achilles; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Menorrhagia
Interventions: Estradiol 30mcg / Levonorgestrel 150mcg monophasic oral contraceptive pills, Naproxen sodium pills, NovaSure® Radiofrequency Endometrial Ablation; Drug · Device
Lead sponsor: Abimbola Famuyide; Other
Eligibility: 30 Years to 55 Years · Female only
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Emergency Contraception
Interventions: DR-104; Drug
Lead sponsor: Duramed Research; Industry
Eligibility: 11 Years to 16 Years · Female only
Enrollment: 343 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 5
States / cities: San Francisco, California • Atlanta, Georgia • Minneapolis, Minnesota + 2 more

Conditions: Depression - Major Depressive Disorder, Irritability
Interventions: Kurvelo, Placebo COC; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 12 Years to 16 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Chapel Hill, North Carolina

Conditions: Dysmenorrhea
Interventions: levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablets, Placebo tablet; Drug
Lead sponsor: Duramed Research; Industry
Eligibility: Up to 17 Years · Female only
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 13
States / cities: Denver, Colorado • Decatur, Georgia • Louisville, Kentucky + 10 more

Conditions: HIV Infections, Contraception, Pharmacokinetics
Interventions: levonorgestrel, efavirenz; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 2
States / cities: Denver, Colorado • Providence, Rhode Island

Conditions: Contraception, Body Weight
Interventions: ethinyl estradiol / levonorgestrel; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Contraception
Interventions: Levonorgestrel/EE 0.15/0.03 mg and EE 0.01 mg tablets; Drug
Lead sponsor: Duramed Research; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 320 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2006
U.S. locations: 11
States / cities: Tucson, Arizona • Washington D.C., District of Columbia • Lincoln, Nebraska + 8 more

Conditions: Healthy Women, Female Contraception
Interventions: levonorgestrel butanoate (LB) injection; Biological
Lead sponsor: Premier Research; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 136 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 7
States / cities: Davis, California • Denver, Colorado • Boston, Massachusetts + 4 more

Conditions: Endometrial Cancer
Interventions: Levonorgestrel intrauterine system; Device
Lead sponsor: University of Medicine and Dentistry of New Jersey; Other
Eligibility: 35 Years to 50 Years · Female only
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Contraception, HIV
Interventions: Levonorgestrel and Ethinyl Estradiol; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: HIV Infections
Interventions: Levonorgestrel-releasing intrauterine device (IUD); Device
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2005
U.S. locations: 8
States / cities: Los Angeles, California • Baltimore, Maryland • Fall River, Massachusetts + 4 more

Conditions: Postpartum Contraception
Interventions: Levonorgestrel-releasing intrauterine system; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Atypical Endometrial Hyperplasia, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma
Interventions: Everolimus, Laboratory Biomarker Analysis, Levonorgestrel-Releasing Intrauterine System; Drug · Other · Device
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2028
U.S. locations: 18
States / cities: Greeley, Colorado • Loveland, Colorado • Honolulu, Hawaii + 11 more

Conditions: Hemostasis, Oral Contraceptive
Interventions: 91-day Levonorgestrel Oral Contraceptive, 28-day Levonorgestrel Oral Contraceptive, 28-day Desogestrel Oral Contraceptive; Drug
Lead sponsor: Teva Women's Health; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 265 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 21
States / cities: San Diego, California • Washington D.C., District of Columbia • Miami, Florida + 16 more

Conditions: Contraception
Interventions: Copper IUD, Levonorgestrel IUD; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 711 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 6
States / cities: Logan, Utah • Ogden, Utah • Orem, Utah + 3 more

Conditions: Complex Atypical Hyperplasia, Endometrial Cancer
Interventions: Metformin; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Cincinnati, Ohio

Conditions: Contraceptive Usage
Interventions: Levonorgestrel IUD; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older · Female only
Enrollment: 93 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Emergency Contraception
Interventions: Etonogestrel implant with Oral Levonorgestrel emergency contraception 1.5mg, Etonogestrel implant with oral placebo; Drug · Device
Lead sponsor: Lori Gawron; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 790 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Pregnancy
Interventions: Mother receives voucher valued at 100% of cost of name-brand IUD (March 4, 2019-March 31, 2023), Mother receives voucher valued at 50% of cost of name-brand IUD (August 26, 2018-March 3, 2019); Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 0 Years to 17 Years
Enrollment: 4,700 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2049
U.S. locations: 9
States / cities: Ann Arbor, Michigan • Detroit, Michigan • Ferndale, Michigan + 6 more

Conditions: Contraception
Interventions: Long Acting Reversible Contraception (LARC), Referral for Long Acting Reversible Contraception (LARC), Prescription for Short-Acting Hormonal Contraception; Drug · Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 17 Years to 30 Years · Female only
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Gresham, Oregon

Conditions: Obesity
Interventions: Levonorgestrel-based emergency contraception 1.5 mg, Levonorgestrel-based emergency contraception 3.0mg; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Portland, Oregon

Search by objective public record fields.

Long-Acting Progestin Contraception and the Vaginal Microbiome

A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants

Study of Immune Cell Changes in the Genital Tract 2 Months After Initiation of an IUD for Contraception

Medical Therapy Versus Radiofrequency Endometrial Ablation in the Initial Treatment of Menorrhagia

Emergency Contraception Actual Use Study

Teen Vulnerability to Irritability: Brain and Estrogen Changes

A Study to Evaluate the Efficacy of Seasonique for the Treatment of Cyclic Pelvic Pain

A Study of the Drug Interactions Between a Hormonal Emergency Contraception and an HIV Medication

Oral Contraceptive Efficacy and Body Weight

A Multicenter Study to Evaluate the Safety of Seasonique, an Oral Contraceptive.

A Study to Evaluate the PK and PD of IM or SQ Injections of Levonorgestrel Butanoate (LB) for Female Contraception

A Randomized, Controlled, Comparative Study of a Levonorgestrel Intrauterine System for the Prevention of Endometrial Cancer in Patients Aged 40-50 With BMI Greater Than 35

Protease Inhibitors and Combined Oral Contraceptive Pharmacokinetics and Pharmacodynamics

Effect of an Intrauterine Contraceptive Device (IUD) in HIV Infected Women

Postpartum Levonorgestrel-releasing Intrauterine System and Breastfeeding

Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer

A Multicenter Study to Evaluate the Effects of a 91-Day Extended Cycle Oral Contraceptive on Hemostatic Parameters in Healthy Women

RAPID EC - Rct Assessing Pregnancy With Intrauterine Devices for EC

Metformin With the Levonorgestrel-Releasing Intrauterine Device for the Treatment of Complex Atypical Hyperplasia (CAH) and Endometrial Cancer (EC) in Non-surgical Patients

'Levonorgestrel IUD Insertion After D&E Procedure

Etonogestrel (ENG) Implant Insertion for Emergency Contraception With Oral Levonorgestrel (LNG) vs Placebo

Michigan Contraceptive Access, Research, and Evaluation Study Children: Phase 1

LARC Forward Contraceptive Counseling at MHCC

Effectiveness of Orally Dosed Emergency Contraception in Obese Women - LNG